A Phase 1 Study of TNG908 in People with Sarcoma, Mesothelioma, or Glioblastoma


Full Title

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors (TNG908-C101)


The purpose of this study is to find the best dose of TNG908 to use in people with advanced cancer. The people in this study have sarcoma, mesothelioma, or glioblastoma that came back or kept growing after treatment. In addition, their tumors do not make a protein called MTAP. TNG908 targets and kills cancer cells that don’t make MTAP. It is a tablet that is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have sarcoma, mesothelioma, or glioblastoma that keeps growing after standard treatment or for which there is no standard treatment.
  • Have completed prior chemotherapy at least 4 weeks and/or radiation therapy at least 2 weeks before taking TNG908.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Mrinal Gounder’s office at 646-888-4167.




Phase I/II (phases 1 and 2 combined)


ClinicalTrials.gov ID